180 related articles for article (PubMed ID: 29930727)
1. A tightly controlled Src-YAP signaling axis determines therapeutic response to dasatinib in renal cell carcinoma.
Sun J; Wang X; Tang B; Liu H; Zhang M; Wang Y; Ping F; Ding J; Shen A; Geng M
Theranostics; 2018; 8(12):3256-3267. PubMed ID: 29930727
[TBL] [Abstract][Full Text] [Related]
2. Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma.
Lue HW; Cole B; Rao SA; Podolak J; Van Gaest A; King C; Eide CA; Wilmot B; Xue C; Spellman PT; Heiser LM; Tyner JW; Thomas GV
Oncotarget; 2015 Dec; 6(42):44675-87. PubMed ID: 26625308
[TBL] [Abstract][Full Text] [Related]
3. A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma.
Suwaki N; Vanhecke E; Atkins KM; Graf M; Swabey K; Huang P; Schraml P; Moch H; Cassidy AM; Brewer D; Al-Lazikani B; Workman P; De-Bono J; Kaye SB; Larkin J; Gore ME; Sawyers CL; Nelson P; Beer TM; Geng H; Gao L; Qian DZ; Alumkal JJ; Thomas G; Thomas GV
Sci Transl Med; 2011 Jun; 3(85):85ra47. PubMed ID: 21632985
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.
Rao G; Kim IK; Conforti F; Liu J; Zhang YW; Giaccone G
Eur J Cancer; 2018 Aug; 99():37-48. PubMed ID: 29902613
[TBL] [Abstract][Full Text] [Related]
5. SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis.
Lamar JM; Xiao Y; Norton E; Jiang ZG; Gerhard GM; Kooner S; Warren JSA; Hynes RO
J Biol Chem; 2019 Feb; 294(7):2302-2317. PubMed ID: 30559289
[TBL] [Abstract][Full Text] [Related]
6. YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity.
Sugihara T; Werneburg NW; Hernandez MC; Yang L; Kabashima A; Hirsova P; Yohanathan L; Sosa C; Truty MJ; Vasmatzis G; Gores GJ; Smoot RL
Mol Cancer Res; 2018 Oct; 16(10):1556-1567. PubMed ID: 29903769
[TBL] [Abstract][Full Text] [Related]
7. Long noncoding RNA TUG1 promotes cell proliferation and migration of renal cell carcinoma via regulation of YAP.
Liu S; Yang Y; Wang W; Pan X
J Cell Biochem; 2018 Dec; 119(12):9694-9706. PubMed ID: 30132963
[TBL] [Abstract][Full Text] [Related]
8. Platelet-derived growth factor regulates YAP transcriptional activity via Src family kinase dependent tyrosine phosphorylation.
Smoot RL; Werneburg NW; Sugihara T; Hernandez MC; Yang L; Mehner C; Graham RP; Bronk SF; Truty MJ; Gores GJ
J Cell Biochem; 2018 Jan; 119(1):824-836. PubMed ID: 28661054
[TBL] [Abstract][Full Text] [Related]
9. LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients.
Kim YJ; Hong S; Sung M; Park MJ; Jung K; Noh KW; Oh DY; Lee MS; Oh E; Shin YK; Choi YL
Oncotarget; 2016 Dec; 7(50):82876-82888. PubMed ID: 27756880
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling.
Xiao J; Xu M; Hou T; Huang Y; Yang C; Li J
Mol Med Rep; 2015 Sep; 12(3):3249-3256. PubMed ID: 25975261
[TBL] [Abstract][Full Text] [Related]
11. Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity.
Teng Y; Cai Y; Pi W; Gao L; Shay C
J Hematol Oncol; 2017 Jun; 10(1):118. PubMed ID: 28606127
[TBL] [Abstract][Full Text] [Related]
12. Regulation of the prometastatic neuregulin-MMP13 axis by SRC family kinases: therapeutic implications.
Orive-Ramos A; Seoane S; Ocaña A; Pandiella A; Montero JC
Mol Oncol; 2017 Dec; 11(12):1788-1805. PubMed ID: 29032615
[TBL] [Abstract][Full Text] [Related]
13. Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma.
Mukaihara K; Tanabe Y; Kubota D; Akaike K; Hayashi T; Mogushi K; Hosoya M; Sato S; Kobayashi E; Okubo T; Kim Y; Kohsaka S; Saito T; Kaneko K; Suehara Y
PLoS One; 2017; 12(9):e0185321. PubMed ID: 28945796
[TBL] [Abstract][Full Text] [Related]
14. S1P/S1PR3 axis promotes aerobic glycolysis by YAP/c-MYC/PGAM1 axis in osteosarcoma.
Shen Y; Zhao S; Wang S; Pan X; Zhang Y; Xu J; Jiang Y; Li H; Zhang Q; Gao J; Yang Q; Zhou Y; Jiang S; Yang H; Zhang Z; Zhang R; Li J; Zhou D
EBioMedicine; 2019 Feb; 40():210-223. PubMed ID: 30587459
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
[TBL] [Abstract][Full Text] [Related]
16. Src Inhibits the Hippo Tumor Suppressor Pathway through Tyrosine Phosphorylation of Lats1.
Si Y; Ji X; Cao X; Dai X; Xu L; Zhao H; Guo X; Yan H; Zhang H; Zhu C; Zhou Q; Tang M; Xia Z; Li L; Cong YS; Ye S; Liang T; Feng XH; Zhao B
Cancer Res; 2017 Sep; 77(18):4868-4880. PubMed ID: 28754671
[TBL] [Abstract][Full Text] [Related]
17. YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.
Garmendia I; Pajares MJ; Hermida-Prado F; Ajona D; Bértolo C; Sainz C; Lavín A; Remírez AB; Valencia K; Moreno H; Ferrer I; Behrens C; Cuadrado M; Paz-Ares L; Bustelo XR; Gil-Bazo I; Alameda D; Lecanda F; Calvo A; Felip E; Sánchez-Céspedes M; Wistuba II; Granda-Diaz R; Rodrigo JP; García-Pedrero JM; Pio R; Montuenga LM; Agorreta J
Am J Respir Crit Care Med; 2019 Oct; 200(7):888-899. PubMed ID: 31166114
[No Abstract] [Full Text] [Related]
18. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
Luo FR; Barrett YC; Yang Z; Camuso A; McGlinchey K; Wen ML; Smykla R; Fager K; Wild R; Palme H; Galbraith S; Blackwood-Chirchir A; Lee FY
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1065-74. PubMed ID: 18301894
[TBL] [Abstract][Full Text] [Related]
19. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
[TBL] [Abstract][Full Text] [Related]
20. Opposite Effects of Src Family Kinases on YAP and ERK Activation in Pancreatic Cancer Cells: Implications for Targeted Therapy.
Sinnett-Smith J; Anwar T; Reed EF; Teper Y; Eibl G; Rozengurt E
Mol Cancer Ther; 2022 Nov; 21(11):1652-1662. PubMed ID: 35999654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
